Carbamazepine: a clinical biopharmaceutical study

Area of Science:

• Biopharmaceutical science
• Pharmacokinetics
• Clinical pharmacology

Background:

• Carbamazepine is an antiepileptic drug with variable absorption.
• Particle size is a critical factor influencing drug dissolution and absorption rates.

Purpose of the Study:

• To compare the absorption rates and clinical significance of two carbamazepine preparations (F-CBZ, DAK vs. Tegretol) with different particle sizes.
• To evaluate the impact of particle size on steady-state plasma levels, side effects, and seizure frequency in epileptic patients.

Main Methods:

• Comparative absorption test in healthy volunteers (single dose).
• Double-blind, randomized, double-dummy cross-over trial in epileptic patients (35 days).
• Analysis of plasma carbamazepine and carbamazepine-10,11-epoxide levels, side effects, and seizure frequency.

Main Results:

• F-CBZ, DAK (smaller particles) showed a more rapid dissolution and absorption rate than Tegretol (larger particles).
• Lower morning steady-state plasma carbamazepine levels were observed with F-CBZ, DAK, but the difference was modest.
• No significant differences in the type or frequency of side effects or seizures were noted between the two preparations.

Conclusions:

• Carbamazepine particle size significantly influences its absorption rate.
• The observed differences in absorption rates between F-CBZ, DAK and Tegretol were not clinically significant regarding steady-state levels, side effects, or seizure control.
• Side effects showed a tendency to correlate with carbamazepine-10,11-epoxide concentration, independent of particle size.